| Targetable genetic features of primary testicular and primary central nervous system lymphomas B Chapuy, MGM Roemer, C Stewart, Y Tan, RP Abo, L Zhang, AJ Dunford, ... Blood, The Journal of the American Society of Hematology 127 (7), 869-881, 2016 | 536 | 2016 |
| MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma SJ Rodig, D Gusenleitner, DG Jackson, E Gjini, A Giobbie-Hurder, C Jin, ... Science translational medicine 10 (450), eaar3342, 2018 | 530 | 2018 |
| Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma CD Carey, D Gusenleitner, M Lipschitz, MGM Roemer, EC Stack, E Gjini, ... Blood, The Journal of the American Society of Hematology 130 (22), 2420-2430, 2017 | 319 | 2017 |
| Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients PB Subrahmanyam, Z Dong, D Gusenleitner, A Giobbie-Hurder, ... Journal for immunotherapy of cancer 6, 1-14, 2018 | 193 | 2018 |
| An aryl hydrocarbon receptor-mediated amplification loop that enforces cell migration in ER−/PR−/Her2− human breast cancer cells O Novikov, Z Wang, EA Stanford, AJ Parks, A Ramirez-Cardenas, ... Molecular pharmacology 90 (5), 674-688, 2016 | 151 | 2016 |
| GeneSigDB: a manually curated database and resource for analysis of gene expression signatures AC Culhane, MS Schröder, R Sultana, SC Picard, EN Martinelli, C Kelly, ... Nucleic acids research 40 (D1), D1060-D1066, 2012 | 145 | 2012 |
| Cancer-germline antigen expression discriminates clinical outcome to CTLA-4 blockade SA Shukla, P Bachireddy, B Schilling, C Galonska, Q Zhan, C Bango, ... Cell 173 (3), 624-633. e8, 2018 | 140 | 2018 |
| Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised … R Dummer, JC Brase, J Garrett, CD Campbell, E Gasal, M Squires, ... The lancet oncology 21 (3), 358-372, 2020 | 138 | 2020 |
| Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525)±anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies P Schöffski, DSW Tan, M Martín, M Ochoa-de-Olza, J Sarantopoulos, ... Journal for immunotherapy of cancer 10 (2), 2022 | 102 | 2022 |
| Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i R Dummer, C Lebbé, V Atkinson, M Mandalà, PD Nathan, A Arance, ... Nature medicine 26 (10), 1557-1563, 2020 | 96 | 2020 |
| Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease B Chapuy, H Cheng, A Watahiki, MD Ducar, Y Tan, L Chen, MGM Roemer, ... Blood, The Journal of the American Society of Hematology 127 (18), 2203-2213, 2016 | 95 | 2016 |
| Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of action D Gusenleitner, SS Auerbach, T Melia, HF Gomez, DH Sherr, S Monti PloS one 9 (7), e102579, 2014 | 71 | 2014 |
| iBBiG: iterative binary bi-clustering of gene sets D Gusenleitner, EA Howe, S Bentink, J Quackenbush, AC Culhane Bioinformatics 28 (19), 2484-2492, 2012 | 62 | 2012 |
| ASSIGN: context-specific genomic profiling of multiple heterogeneous biological pathways Y Shen, M Rahman, SR Piccolo, D Gusenleitner, NN El-Chaar, L Cheng, ... Bioinformatics 31 (11), 1745-1753, 2015 | 42 | 2015 |
| Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma GK Griffin, JL Weirather, MGM Roemer, M Lipschitz, A Kelley, PH Chen, ... Blood, The Journal of the American Society of Hematology 137 (10), 1353-1364, 2021 | 37 | 2021 |
| RamiGO: an R/Bioconductor package providing an AmiGO visualize interface MS Schröder, D Gusenleitner, J Quackenbush, AC Culhane, ... Bioinformatics 29 (5), 666-668, 2013 | 37 | 2013 |
| Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens CD Carey, D Gusenleitner, B Chapuy, AE Kovach, MJ Kluk, HH Sun, ... The Journal of Molecular Diagnostics 17 (1), 19-30, 2015 | 31 | 2015 |
| GCOD-GeneChip Oncology Database F Liu, J White, C Antonescu, J Quackenbush BMC bioinformatics 12 (1), 46, 2011 | 21 | 2011 |
| Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma R Váraljai, L Zimmer, Y Al-Matary, P Kaptein, LJ Albrecht, B Shannan, ... Nature cancer 4 (9), 1292-1308, 2023 | 13 | 2023 |
| Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 … HA Tawbi, C Robert, JC Brase, D Gusenleitner, E Gasal, J Garrett, ... Journal for immunotherapy of cancer 10 (6), 2022 | 13 | 2022 |
Scott RodigProfessor of Pathology, Brigham & Women's Hospital在 bwh.harvard.edu 的电子邮件经过验证
